ANN ARBOR—The pharmaceutical firm Esperion Therapeutics Inc. feported a rise in sales of its novel cholesterol-reducing drugs in the second quarter ended June 30 but still posted a loss as efforts to boost the drug’s sales continue. The company posted a loss of $43.7 million or $1.67 a share in the quarter, compared to net
ANN ARBOR — Esperion Therapeutics Inc. announced positive top-line results from the third of five pivotal Phase 3 studies expected to be reported this year to evaluate the efficacy in lowering so-called bad cholesterol. The tests were done on Esperion's, lead drug candidate, bempedoic acid, at a dose of 180 milligrams, vs. placebo in high-risk patients
LANSING - Michigan's changes in 2012 to the rules governing reimbursement for physician-dispensed prescriptions for workers' compensation claims have so far not seen major increases in new strengths or new formulations of certain pain-relieving medications, but the trend is growing across numerous other states, including neighboring Illinois, a study has found. The Workers Compensation Research
ALLEGAN - Mylan NV lost its $26 billion hostile bid for Perrigo Co. after a seven-month pursuit, a rare outcome in what shaped up to be one of the most bitter takeover battles in decades, the Wall Street Journal reported Friday. Mylan said that about 40 percent of Perrigo’s shares were tendered in the offer. It needed at
